VAY RE-HIT: Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab (clinicaltrials.gov) - Oct 16, 2026 - P2 | N=0 | Withdrawn | Sponsor: Novartis Pharmaceuticals | N=60 ➔ 0 | Recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura
|